Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 31 to 40 of 484 total matches.
Twirla - A New Contraceptive Patch
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
-label trial
(SECURE) that included 1736 women 18-35 years old
who completed 15,165 evaluable 28-day ...
The FDA has approved Twirla (Agile Therapeutics),
a transdermal contraceptive patch containing the
estrogen ethinyl estradiol and the progestin
levonorgestrel, for use in women with a BMI <30 kg/m2.
It is the second contraceptive patch to become
available in the US; Xulane, a patch that delivers
ethinyl estradiol and the progestin norelgestromin,
has been available since 2014.
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
days previously and
had one or more risk factors for progression to
severe COVID-19 (e.g., age ≥60 ...
The IV antiviral drug remdesivir (Veklury – Gilead)
has been available for treatment of COVID-19 in
hospitalized patients since 2020. Now, the FDA has
approved remdesivir for treatment of mild to moderate
COVID-19 in outpatients ≥12 years old who weigh
≥40 kg and are at high risk for progression to severe
disease, including hospitalization or death; they
also issued an Emergency Use Authorization (EUA)
allowing its use in any other high-risk outpatient who
weighs ≥3.5 kg.
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
peptides
Half-life (elimination) 4.5 days
Teplizumab-mzwv (Tzield – Provention Bio), an anti-
CD3 ...
Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the
FDA to delay the onset of stage 3 type 1 diabetes
in patients ≥8 years old who have stage 2 type 1
diabetes. It is the first drug to become available in the
US that delays the onset of type 1 diabetes.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):7-8 doi:10.58347/tml.2023.1667c | Show Introduction Hide Introduction
Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder (online only)
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
/day titrated to
63 mg/kg/day; >28 kg: 450 mg/day titrated to 1800 mg/day.
▶ Cost: 30 days ...
The FDA has approved ganaxolone (Ztalmy – Marinus)
for oral treatment of seizures associated with cyclin-dependent
kinase-like 5 (CDKL5) deficiency disorder
in patients ≥2 years old. It is the first drug to be
approved in the US for this indication.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):e139-40 doi:10.58347/tml.2024.1709g | Show Introduction Hide Introduction
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024 (Issue 1703)
such as the Dietary Approaches
to Stop Hypertension (DASH) diet,2 limiting intake
of sodium (ideally ...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 doi:10.58347/tml.2024.1703a | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
)
5.8 g/teaspoon powder; 5.8 g
packets; 1.8 g caps; 2 g wafers
$29.00
10-35 g/day in 2-3 divided ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3 doi:10.58347/tml.2025.1721f | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
buprenorphine levels with 32 mg
once weekly or 128 mg once
monthly ~60% higher than those
with 24 mg/day ...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e144-5 doi:10.58347/tml.2023.1684b | Show Introduction Hide Introduction
COVID-19 Update: Metformin to Prevent Long Covid?
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
years old with
an elevated body mass index who had tested positive
for SARS-CoV-2 infection ≤3 days ...
Results from a double-blind trial suggest that off-label
use of the oral antihyperglycemic drug metformin
in patients with COVID-19 may decrease the risk
of post-acute sequelae of SARS-CoV-2 infection
("long COVID").
Med Lett Drugs Ther. 2023 May 29;65(1677):87-8 doi:10.58347/tml.2023.1677e | Show Introduction Hide Introduction
In Brief: Alternatives to Mifepristone for Medication Abortion
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
(expulsion of
the gestational sac without surgical intervention) of
97% in pregnancies of up to 70 days ...
The possibility that use of mifepristone (Mifeprex,
and generics) may be restricted has led to questions
about alternatives for medication abortion.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):102-3 doi:10.58347/tml.2023.1679d | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
x 1 dose,
then 200 mg PO 12 hrs later on
day 1, followed by 200 mg PO bid
$16.20
937.80 ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction